Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert L Coleman

Showing results (1-10 of 496) with videos related to

Pageof 50
Sort By:
Current Oncology Reports|November 9, 2006
Intraperitoneal chemotherapy for frontline ovarian cancer therapy: vindicated or vilified?Robert L Coleman
The New England Journal of Medicine|February 14, 2020
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. ReplyRobert L Coleman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 23, 2023
PARP inhibitor era: current status and future directionsRobert L Coleman
Expert Review of Anticancer Therapy|February 10, 2007
7th annual International Conference on Ovarian CancerRobert L Coleman
Journal of Gynecologic Oncology|December 10, 2020
The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?Robert L Coleman
Clinical Advances in Hematology & Oncology : H&O|July 21, 2023
Highlights from the 2023 American Society of Clinical Oncology Annual Meeting: gynecologic cancerRobert L Coleman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 21, 2020
Innovation abounds in cancer therapyRobert L Coleman
The Oncologist|September 27, 2002
Emerging role of topotecan in front-line treatment of carcinoma of the ovaryRobert L Coleman
Annals of Surgical Oncology|December 31, 2003
Primary vaginal melanoma: a rare and problematic clinical entityRobert L Coleman
Current Oncology Reports|November 10, 2007
Gemcitabine plus carboplatin compared with carboplatin alone for platinum-sensitive recurrent ovarian cancerRobert L Coleman
Pageof 50

Showing results (1-10 of 496) with videos related to

Sort By:
Pageof 50
Current Oncology Reports|November 9, 2006
Intraperitoneal chemotherapy for frontline ovarian cancer therapy: vindicated or vilified?Robert L Coleman
The New England Journal of Medicine|February 14, 2020
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. ReplyRobert L Coleman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 23, 2023
PARP inhibitor era: current status and future directionsRobert L Coleman
Expert Review of Anticancer Therapy|February 10, 2007
7th annual International Conference on Ovarian CancerRobert L Coleman
Journal of Gynecologic Oncology|December 10, 2020
The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?Robert L Coleman
Clinical Advances in Hematology & Oncology : H&O|July 21, 2023
Highlights from the 2023 American Society of Clinical Oncology Annual Meeting: gynecologic cancerRobert L Coleman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 21, 2020
Innovation abounds in cancer therapyRobert L Coleman
The Oncologist|September 27, 2002
Emerging role of topotecan in front-line treatment of carcinoma of the ovaryRobert L Coleman
Annals of Surgical Oncology|December 31, 2003
Primary vaginal melanoma: a rare and problematic clinical entityRobert L Coleman
Current Oncology Reports|November 10, 2007
Gemcitabine plus carboplatin compared with carboplatin alone for platinum-sensitive recurrent ovarian cancerRobert L Coleman
Pageof 50